AstraZeneca [NASDAQ: AZN] COVID19 Vaccine Safety Confirms in Large Trial

The COVID-19 vaccine of AstraZeneca plc [NASDAQ: AZN] which was created in collaboration with Oxford University was proven to be 79% effective in a large trial in the US. The result of the new trial has opened the door for the vaccine to get authorization from US authorities. The firm has disclosed on Monday that its vaccine is 100% safe to prevent hospitalization and save people from a serious illness.

AstraZeneca and Oxford University have conducted a large trial with almost 32,000 participants to prove the safety of its vaccine. The study found out that the vaccine is also safe for people above 65 as it is safe for people below 65. The authorities of America had earlier forced the firm to carry out the extra trial to prove its safety.

In the past few days, the firm has faced pressure because dozen of European countries have stopped the use of vaccines with the fear that it could cause blood clots but after the trial’s results it has been proved that the dose of the vaccine is safe. In the large trial almost 141 cases of symptomatic COVID-19 were reported.

AZN also revealed that an independent committee has also carried out a close review of the blood clots in the US trial. It has been disclosed that the CVST extremely rare blood clot in the brain, with the aid of an independent neurologist. The firm also disclosed that it has not found any risk of thrombosis. AstraZeneca revealed that it is intending to submit the data to the U.S. FDA and also planning to roll out the vaccine in the US.